{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 458283142
| image =  
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = u
| target = endotoxin
<!-- Clinical data -->
| tradename =  
| Drugs.com = {{drugs.com|international|nebacumab}}
| pregnancy_AU =  
| pregnancy_US =  
| pregnancy_category =  
| legal_AU =  
| legal_CA =  
| legal_UK =  
| legal_US =  
| legal_status =  
| routes_of_administration =  
<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 138661-01-5
| ATC_prefix = J06
| ATC_suffix = BC01
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D05126
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
<!-- Chemical data -->
| chemical_formula =  
| molecular_weight =  
}}

'''Nebacumab''' is a [[human]] [[monoclonal antibody]] developed for the treatment of [[sepsis]].<ref>{{Cite journal| first1 = B.| first2 = J.
| last1 = Derkx| first3 = R.
| title = Randomized, Placebo‐Controlled Trial of HA‐1A, a Human Monoclonal Antibody to Endotoxin, in Children with Meningococcal Septic Shock
| journal = Clinical Infectious Diseases
| volume = 28| issue = 4
| pages = 770–7
| year = 1999| pmid = 10825037 
| doi = 10.1086/515184
| last2 =  Wittes
| last3 =  McCloskey
}}</ref> It has been withdrawn in 1993 because it failed to reduce mortality in [[clinical trial]]s.<ref>[http://apps.who.int/medicinedocs/en/d/Js4902e/4.1.262.html#Js4902e.4.1.262 WHO: Consolidated List of Products]</ref>

==References==
{{reflist}}

{{Monoclonals for infectious disease and toxins}}
{{Immune sera and immunoglobulins}}

[[Category:Monoclonal antibodies]]
[[Category:Withdrawn drugs]]
[[Category:Abandoned drugs]]


{{antiinfective-drug-stub}}
{{monoclonal-antibody-stub}}